Milestone
Bath University spin-out Glythera Ltd has met key technical and commercial milestones as part of its investment agreement with the university’s Crescent Seedcorn fund and IP Group, triggering the second tranche of a £500,000 investment to further advance its research in protein/peptide functionalisation and glycosylation technologies.
The technical milestones achieved include the validation of Glythera’s PermaLink technology for attaching functional molecules such as carbohydrates at defined locations on therapeutic proteins, vaccines and peptides.
Meanwhile, the commercial milestones achieved include partnerships with four pharmaceutical companies and governmental research organisations. Further partnerships will be announced in due course.
“The current financing puts us on a firm footing to continue with the commercialisation of our Permalink and PermaCarb technologies enabling us to partner with pharma and biotech,” said Executive Chairman Dr Anthony Baxter.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
